Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [4] - The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer [4]. Upcoming Conference Call - Lucid Diagnostics will host a business update conference call and webcast on August 13, 2025, at 8:30 AM ET [1]. - The call will feature Lishan Aklog, M.D., the Chairman and CEO, providing a business update and overview of the company's operations and growth strategy [1]. - Dennis McGrath, the CFO, will discuss the company's second quarter 2025 financial results during the call [1]. Access Information - The webcast will be available on the investor relations section of the company's website [2]. - U.S.-based callers can access the conference call by dialing 1-800-836-8184, while international listeners should dial 1-646-357-8785 [2]. - A replay of the conference call will be available for 30 days on the investor relations section of the company's website [3]. Product Information - Lucid's EsoGuard® Esophageal DNA Test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients [4]. - The test is performed on samples collected using the EsoCheck® Esophageal Cell Collection Device, which involves a brief, noninvasive office procedure [4].